share_log

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga ·  Apr 5 12:31

Gainers

  • Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million.
  • Galectin Therapeutics (NASDAQ:GALT) shares increased by 20.66% to $3.62. The company's market cap stands at $224.0 million.
  • Ocugen (NASDAQ:OCGN) stock moved upwards by 17.88% to $1.78. The company's market cap stands at $456.7 million. As per the press release, Q4 earnings came out 3 days ago.
  • Processa Pharma (NASDAQ:PCSA) shares moved upwards by 17.67% to $2.73. The market value of their outstanding shares is at $4.6 million.
  • bioAffinity Technologies (NASDAQ:BIAF) stock rose 15.5% to $2.98. The market value of their outstanding shares is at $33.1 million. The company's, Q4 earnings came out 4 days ago.
  • GlucoTrack (NASDAQ:GCTK) shares moved upwards by 15.2% to $0.46. The company's market cap stands at $12.3 million.

Losers

  • Acorda Therapeutics (NASDAQ:ACOR) stock decreased by 17.1% to $1.39 during Friday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q4 earnings came out 4 days ago.
  • Aesthetic Medical Intl (NASDAQ:AIH) shares fell 16.83% to $0.43. The market value of their outstanding shares is at $20.2 million.
  • Ontrak (NASDAQ:OTRK) stock declined by 15.39% to $0.33. The market value of their outstanding shares is at $14.0 million.
  • Kintara Therapeutics (NASDAQ:KTRA) shares fell 15.25% to $0.12. The market value of their outstanding shares is at $4.7 million.
  • Trxade Health (NASDAQ:MEDS) shares declined by 14.33% to $8.67. The company's market cap stands at $10.4 million.
  • eFFECTOR Therapeutics (NASDAQ:EFTR) stock fell 13.86% to $2.55. The company's market cap stands at $9.4 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment